Art

J-GLOBAL ID：201202202254562873   Reference number：12A0850761

進行性腎細胞癌に対する治療戦略-Yamagata Strategyの現状と展望-

Author (2)： KATO TOMOYUKI (山形大 医 腎泌尿器外科) ,  TOMITA YOSHIHIKO (山形大 医 腎泌尿器外科)
Material： 泌尿器外科  (Japanese Journal of Urological Surgery)
Volume： 25  Issue： 臨時増刊  Page： 969-971  Publication year： May. 15, 2012 
JST Material Number： L0465A  ISSN： 0914-6180  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： cytokine therapy ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=12A0850761&from=J-GLOBAL&jstjournalNo=L0465A") }}

JST classification (2)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (5)：

• 1) Motzer RJ, Hutson TE, TomczacP, et al Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007
• 2) Motzer Rj, Hutson TE, TomczacP, et al Overall survival and updated results for sunitinib compared with interferon alfa in patients with meta-static renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009
• 3) Naito S, Yamamoto N, Takayama T, et al Prognosis Japanese metastatic renal cell carcinoma patients in the cytokine era a cooperative group report of 1463. patients. Eur Urol 57: 317-326, 2010
• 4) Akaza H, Kawai K, Tsukamoto T, et al Successful outcomes using combination therapy of interleukin-2 and interferon-alfa for renal cell carcinoma patients with lung metastasis. jpn J Clin Oncol 40: 684-689, 2010
• 5) Fyfe G, Fisher RI, Rosenberg SA, et al Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995

Terms in the title (4)： 進行性腎細胞癌 ,  治療戦略 ,  現状 ,  展望